Fig. 2From: Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention Cumulative drug release profile of voriconazole (VRC) and its optimised Lipid-polymer hybrid nanoparticles (LPH NPs) in PBS 7.4, for a period of 48 h. Data is expressed as mean ± SD (n = 3)Back to article page